Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
NCT04768491
·
clinicaltrials.gov ↗
UNKNOWN
Status
82
Enrollment
OTHER
Sponsor class
Conditions
EGFR Activating Mutation
NSCLC Stage IV
NSCLC Stage IIIB
NSCLC, Recurrent
Interventions
DRUG:
Dacomitinib
Sponsor
Peking Union Medical College